Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), Division of Hematology, SERGAS, Santiago de Compostela, Spain.
Sci Rep. 2020 Feb 12;10(1):2407. doi: 10.1038/s41598-020-59243-5.
Mutations in non-coding DNA regions are increasingly recognized as cancer drivers. These mutations can modify gene expression in cis or by inducing high-order chormatin structure modifications with long-range effects. Previous analysis reported the detection of recurrent and functional non-coding DNA mutations in the chronic lymphocytic leukemia (CLL) genome, such as those in the 3' untranslated region of NOTCH1 and in the PAX5 super-enhancer. In this report, we used whole genome sequencing data produced by the International Cancer Genome Consortium in order to analyze regions with previously reported regulatory activity. This approach enabled the identification of numerous recurrently mutated regions that were frequently positioned in the proximity of genes involved in immune and oncogenic pathways. By correlating these mutations with expression of their nearest genes, we detected significant transcriptional changes in genes such as PHF2 and S1PR2. More research is needed to clarify the function of these mutations in CLL, particularly those found in intergenic regions.
非编码 DNA 区域的突变越来越被认为是癌症的驱动因素。这些突变可以通过顺式或诱导高阶染色质结构修饰来改变基因表达,从而产生远程效应。之前的分析报告在慢性淋巴细胞白血病 (CLL) 基因组中检测到了反复出现的、具有功能的非编码 DNA 突变,如 NOTCH1 3'非翻译区和 PAX5 超级增强子中的突变。在本报告中,我们使用国际癌症基因组联合会产生的全基因组测序数据来分析先前报道的具有调节活性的区域。这种方法能够识别出许多经常位于免疫和致癌途径相关基因附近的反复突变区域。通过将这些突变与它们最近的基因表达相关联,我们检测到了 PHF2 和 S1PR2 等基因的显著转录变化。需要进一步的研究来阐明这些突变在 CLL 中的功能,特别是那些在基因间区域发现的突变。